Clinical Trial Update: A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SHR-A1811 as a monotherapy or in combination with Pyrotinib maleate as neoadjuvant treatment for HER2-positive breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib maleate (pyrotinib)
• SHR-A1811

Snippet

Sponsor: Shengjing Hospital | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING